secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rapport Therapeutics, Inc. (RAPP)
CIK:        0002012593
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0000950170-25-104557
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rapport Therapeutics Q2 net loss $26.7M; RAP-219 Phase 2a topline due Sept 2025, cash runway through 2026
--------------------------------------------------------------------------------

- Net loss of $26.7M for Q2 2025 vs $18.1M YoY; R&D expenses $22.7M and G&A $6.8M.
- RAP-219 Phase 2a trial in drug-resistant focal onset seizures fully enrolled; topline results expected September 2025.
- Phase 2 trial of RAP-219 in bipolar mania initiated; topline results anticipated first half of 2027.
- Cash, equivalents, and short-term investments $260.4M as of June 30, 2025, sufficient to fund operations through end of 2026.
- Phase 1 safety: no SAEs; all TEAEs Grade 1 or 2; most common headache (n=12), dry mouth (5), brain fog (5), fatigue (5).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2012593/000095017025104557/0000950170-25-104557-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2012593/000095017025104557/rapp-20250807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-104557

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer